SCIB1

SCIB1 is a DNA plasmid vaccine that is being developed for the treatment of melanoma. It is designed to stimulate an immune response against a specific protein found on the surface of melanoma cells, known as gp100.

Mechanism of Action

SCIB1 works by stimulating the body's immune system to recognize and attack melanoma cells. It does this by encoding a sequence of DNA that produces a protein called gp100, which is found on the surface of melanoma cells. When the vaccine is injected into the body, it enters cells and uses the cell's machinery to produce the gp100 protein. This protein is then displayed on the surface of the cell, where it can be recognized by the immune system. This triggers an immune response, with the immune system producing T cells that are specifically targeted against gp100. These T cells can then recognize and kill melanoma cells that display the gp100 protein.

Clinical Trials

Several clinical trials have been conducted to test the safety and efficacy of SCIB1. In a Phase 1/2 trial, SCIB1 was found to be safe and well-tolerated, with no serious adverse events reported. In addition, the vaccine was found to induce a strong immune response against gp100, with the majority of patients showing an increase in gp100-specific T cells.

A Phase 2 trial is currently underway to further evaluate the safety and efficacy of SCIB1 in patients with stage III/IV melanoma. This trial is expected to complete in 2022.

Potential Applications

If successful, SCIB1 could provide a new treatment option for patients with melanoma, particularly those with advanced disease. In addition, the vaccine could potentially be used in combination with other treatments, such as checkpoint inhibitors, to enhance the overall immune response against melanoma.

See Also

• Melanoma
• Cancer vaccine
• Immunotherapy

References

SCIB1 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia